These innovative compounds represent a significant leap in the management of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in controlling blood glucose levels. https://theresahwcp207215.smblogsites.com/39216676/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide